S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)

MaxCyte (MXCT) Stock Price, News & Analysis

$4.30
-0.02 (-0.46%)
(As of 12:33 PM ET)
Today's Range
$4.18
$4.34
50-Day Range
$3.94
$5.22
52-Week Range
$2.45
$5.55
Volume
249,461 shs
Average Volume
672,656 shs
Market Capitalization
$447.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67

MaxCyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.6% Upside
$8.67 Price Target
Short Interest
Bearish
3.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$25,600 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.51) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

Medical Sector

450th out of 939 stocks

Commercial Physical Research Industry

7th out of 10 stocks

MXCT stock logo

About MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
MaxCyte Signs SPL Agreement With Imugene
COMM, NKTX and AVIR are among after hour movers
MaxCyte gets new CEO and President
MaxCyte Names Maher Masoud CEO
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:MXCT
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+100.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-37,920,000.00
Pretax Margin
-91.85%

Debt

Sales & Book Value

Annual Sales
$41.29 million
Book Value
$2.23 per share

Miscellaneous

Free Float
97,851,000
Market Cap
$449.71 million
Optionable
Optionable
Beta
1.36
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Maher Masoud (Age 48)
    President, CEO, Secretary & Director
    Comp: $612.07k
  • Mr. Douglas Arthur Doerfler (Age 68)
    Founder & Advisor
    Comp: $1.2M
  • Mr. Douglas J. Swirsky CFA (Age 55)
    CPA, Chief Financial Officer
  • Mr. Jay Gelfman
    Senior Vice President of Operations
  • Mr. Ronald Evan Holtz CPA (Age 66)
    Ph.D., Executive Vice President of Administration
    Comp: $649.38k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. David Sandoval
    Senior Vice President & General Counsel
  • Mr. Thomas Michael Ross (Age 63)
    Executive Vice President of Global Sales
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Ms. Jill Mayer
    Senior Vice President of Human Resources

MXCT Stock Analysis - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings
or view top-rated stocks.

What is MaxCyte's stock price target for 2024?

4 Wall Street analysts have issued 1-year price targets for MaxCyte's stock. Their MXCT share price targets range from $7.00 to $11.00. On average, they predict the company's stock price to reach $8.67 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price.
View analysts price targets for MXCT
or view top-rated stocks among Wall Street analysts.

How have MXCT shares performed in 2024?

MaxCyte's stock was trading at $4.70 at the beginning of the year. Since then, MXCT shares have decreased by 8.1% and is now trading at $4.32.
View the best growth stocks for 2024 here
.

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our MXCT earnings forecast
.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte updated its FY 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29.6 million-$31.3 million, compared to the consensus revenue estimate of $42.1 million.

When did MaxCyte IPO?

MaxCyte (MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cadian Capital Management LP (5.43%), Vanguard Group Inc. (5.08%), Vanguard Group Inc. (5.07%), Massachusetts Financial Services Co. MA (2.44%), Mudita Advisors LLP (1.81%) and River Global Investors LLP (1.46%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends
.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MXCT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners